Prelude Therapeutics Inc (PRLD): Total Assets
$141.31M
As of 2025-12-31
$189.36M
As of 2026-06-30
-13.8%
3-year compound annual growth
-8.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $141.31M | -19.5% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $175.51M | -36.8% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $277.67M | +25.9% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $220.50M | -27.7% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $305.10M | +36.5% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $223.59M | +922.3% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $21.87M | n/a | 2021-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $38.32M | -28.3% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $8.52M | +160.9% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $240.29M | +574.7% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.96M | -12.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $91.52M | -41.8% |
Compare PRLD, EMMA, JAGX, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗